EA200501197A1 - Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1 - Google Patents

Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1

Info

Publication number
EA200501197A1
EA200501197A1 EA200501197A EA200501197A EA200501197A1 EA 200501197 A1 EA200501197 A1 EA 200501197A1 EA 200501197 A EA200501197 A EA 200501197A EA 200501197 A EA200501197 A EA 200501197A EA 200501197 A1 EA200501197 A1 EA 200501197A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptides
igsf9
liv
methods
treatment
Prior art date
Application number
EA200501197A
Other languages
English (en)
Inventor
Карен Маклахлан
Скотт Глэйзер
Роберт Дж. Пич
Тони Роуэ
Original Assignee
Байоджен Айдек Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Ма Инк. filed Critical Байоджен Айдек Ма Инк.
Publication of EA200501197A1 publication Critical patent/EA200501197A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Описаны человеческие полипептиды IGSF9 и LIV-1 и кодирующая такие полипептиды ДНК (РНК). Описанные полипептиды и/или полинуклеотид особенно пригодны для получения модифицированных и природных антител, связывающихся с IGSF9 или LIV-1. Также описаны фармацевтические композиции и вакцины, содержащие антитела, полипептиды и полинуклеотиды согласно изобретению. Также описаны способы применения таких полипептидов для выявления лигандов, антагонистов и агонистов указанных полипептидов. Наконец, описаны способы, включающие в себя указанные выше композиции для лечения, диагностики и/или прогноза неопластических нарушений.
EA200501197A 2003-01-27 2004-01-27 Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1 EA200501197A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44253503P 2003-01-27 2003-01-27
PCT/US2004/002044 WO2004066933A2 (en) 2003-01-27 2004-01-27 Compositions and methods for treating cancer using igsf9 and liv-1

Publications (1)

Publication Number Publication Date
EA200501197A1 true EA200501197A1 (ru) 2006-04-28

Family

ID=32825236

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501197A EA200501197A1 (ru) 2003-01-27 2004-01-27 Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1

Country Status (16)

Country Link
US (2) US20040258616A1 (ru)
EP (1) EP1596806A4 (ru)
JP (1) JP2006520194A (ru)
KR (1) KR20050102627A (ru)
CN (1) CN1849337A (ru)
AU (1) AU2004207538A1 (ru)
BR (1) BRPI0407031A (ru)
CA (1) CA2514062A1 (ru)
EA (1) EA200501197A1 (ru)
IS (1) IS7960A (ru)
MX (1) MXPA05007940A (ru)
NO (1) NO20053986L (ru)
PL (1) PL379264A1 (ru)
RS (1) RS20050577A (ru)
WO (1) WO2004066933A2 (ru)
ZA (1) ZA200506671B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2608646C2 (ru) * 2010-12-06 2017-01-23 Сиэтл Генетикс, Инк. Гуманизированные антитела к LIV-1 и их применение для лечения рака

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) * 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
EP1709976A4 (en) * 2003-12-26 2007-10-17 Toshio Hirano EMT-INDUCING MEDIUM
WO2006014999A2 (en) * 2004-07-27 2006-02-09 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
EP2407483A1 (en) * 2006-04-13 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Methods of treating, diagnosing or detecting cancers
KR20110091423A (ko) * 2010-02-05 2011-08-11 국립암센터 항―ｔｍａｐ／ｃｋａｐ２ 항체를 포함하는 암의 예후 진단용 조성물
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
JP7265788B2 (ja) * 2017-05-09 2023-04-27 シアノ バイオテック ゲーエムベーハー 修飾ミクロシスチンおよびノジュラリン
CN110563845A (zh) * 2019-09-12 2019-12-13 滨州医学院 抗igsf9抗体、药物组合物及其应用
KR20210122185A (ko) * 2020-03-31 2021-10-08 웰마커바이오 주식회사 Igsf1에 대한 항체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 이를 이용한 암 치료 방법
CN116082503B (zh) * 2022-08-19 2023-08-04 滨州医学院 一种靶向人igsf9的单克隆抗体及其应用
WO2024109944A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 抗liv-1抗体、其药物偶联物及其医药用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5099069A (en) * 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
AU633698B2 (en) * 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) * 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0669986T3 (da) * 1992-11-13 2003-07-28 Idec Pharma Corp Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
EP0752248B1 (en) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2132500A1 (en) * 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
CA2395832A1 (en) * 2000-01-25 2001-08-02 Genentech, Inc. Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
AU2001290548A1 (en) * 2000-09-11 2002-03-26 Hyseq, Inc. Novel nucleic acids and polypeptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2608646C2 (ru) * 2010-12-06 2017-01-23 Сиэтл Генетикс, Инк. Гуманизированные антитела к LIV-1 и их применение для лечения рака

Also Published As

Publication number Publication date
CA2514062A1 (en) 2004-08-12
MXPA05007940A (es) 2007-06-14
JP2006520194A (ja) 2006-09-07
AU2004207538A1 (en) 2004-08-12
KR20050102627A (ko) 2005-10-26
WO2004066933A3 (en) 2006-03-02
RS20050577A (en) 2007-09-21
BRPI0407031A (pt) 2006-01-17
IS7960A (is) 2005-07-27
WO2004066933A2 (en) 2004-08-12
NO20053986L (no) 2005-10-27
NO20053986D0 (no) 2005-08-26
EP1596806A2 (en) 2005-11-23
CN1849337A (zh) 2006-10-18
EP1596806A4 (en) 2007-08-29
ZA200506671B (en) 2006-09-27
PL379264A1 (pl) 2006-08-07
US20040258616A1 (en) 2004-12-23
US20070071674A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
WO2001055350A8 (en) Nucleic acids, proteins, and antibodies
ATE410446T1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
NO20053986L (no) Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1.
DE60235041D1 (de) Und ihre verwendung
ATE330967T1 (de) An her2 bindende peptidverbindungen
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
MX2008009886A (es) Anticuerpos que enlazan par-2.
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2003105773A3 (en) MUTATIONS OF PDGFRA ACTIVATED AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2002079398A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE397673T1 (de) Verstärktes krebs-gen wip1
ATE496129T1 (de) Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
WO2003076651A3 (en) Cancer associated araf1 protein kinase and its uses
IL155687A0 (en) Polynucleotides encoding hlrrsi1 polypeptides
WO2004063226A3 (en) Novel fibrillin-like polypeptides
ATE521623T1 (de) Neues, bei prostatakrebs exprimiertes gen und verwendungsverfahren
WO2004031233A3 (en) Novel chemokine-like polypeptides